The application software company SAP AG is set to begin offering a personalized treatment option service for qualified employees fighting cancer, in partnership with MolecularHealth and GATC Biotech. The program will offer personalized tumor analysis in order to offer clinical interpretation and genomic patient data for helping physicians make informed decisions on individualized treatments.
The sequenced data will be processed through an ultra-fast genome alignment algorithm, included in the SAP Genomic Analyzer solution, which is used to collect the full DNA exome sequencing. The algorithm reduces the processing data time to three minutes, which is about 300 times faster than the previous alignment software.
The sequencing data processed by MolecularHealth’s TreatmentMAP will only be available to oncologists who are treating SAP employees, and the company expects that it will be especially useful for patients diagnosed with solid tumor cancers. However, while the integrated service increases the number of treatment options by providing data, it is up to the oncologist, in collaboration with the patient, to decide the best course of treatment.
While MolecularHealth’s Treatment software will form the basis of the new service in the United States, with the company planning on launching its own CLIA-certified sequencing lab, in Europe, the sequencing platform will be supplied by GATC Biotech. This is the first medical system of its kind for personalized cancer medicine registered in Europe. The service will be implemented in two countries, although employees in other nations will benefit from it in the future, according to a company press release.
Personalized treatment is a result of the developments in the genetic sequencing field, as well as in the processing power of technologies. SAP expects that MolecularHealth’s TreatmentMAP will change the way in which the fight against cancer is done. The next goals are to decrease the costs and to make this personal`ed treatment available for more people.